Ganirelix acetate

编号: 20561

Cas号: 123246-29-7

纯度: 98% Min.

Ganirelix is is an antagonist of GnRH that competitively antagonizes the gonadotropic GnRH receptor, thereby mutating the pathway and causing rapid and reversible inhibition of gonadotropin (luteinizing hormone LH and follicle stimulating hormone FSH) secretion. Ganirelix Acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by Ganirelix Acetate is more pronounced than that of FSH.

仅供研究使用。我们不向患者出售。

化学信息

名称	Ganirelix acetate
Iupac 化学名称	(S)-1-(N2-N2-((R)-2-((R)-2-((R)-2-acetamido-3-(naphthalen-2-yl)propanamido)-3-(4-chlorophenyl)propanamido)-3-(pyridin-3-yl)propanoyl)-L-seryl-L-tyrosyl-N6-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-N6-(bis(ethylamino)methylene)-L-lysyl)-N-((R)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide diacetate
同义词	D 24598; D-24598; D24598; Ganirelix; Orgalutran; RS 26306; RS26306; RS-26306;
英文同义词	D 24598; D-24598; D24598; Ganirelix; Orgalutran; RS 26306; RS26306; RS-26306;
分子式	C84H121ClN18O17
分子量	1690.42
Smile	C[C@H](C(N)=O)NC([C@H]1N(C([C@H](CCCC/N=C(NCC)/NCC)NC([C@H](CC(C)C)NC([C@@H](CCCC/N=C(NCC)/NCC)NC([C@H](CC2=CC=C(O)C=C2)NC([C@H](CO)NC([C@@H](CC3=CC=CN=C3)NC([C@@H](CC4=CC=C(Cl)C=C4)NC([C@@H](CC5=CC=C6C=CC=CC6=C5)NC(C)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC1)=O.CC(O)=O.CC(O)=O
InChiKey	OVBICQMTCPFEBS-SATRDZAXSA-N
InChi	InChI=1S/C80H113ClN18O13.2C2H4O2/c1-9-84-79(85-10-2)88-38-17-15-24-60(70(104)94-62(41-49(5)6)71(105)93-61(25-16-18-39-89-80(86-11-3)87-12-4)78(112)99-40-20-26-68(99)77(111)90-50(7)69(82)103)92-73(107)64(44-53-30-35-59(102)36-31-53)97-76(110)67(48-100)98-75(109)66(46-55-21-19-37-83-47-55)96-74(108)65(43-52-28-33-58(81)34-29-52)95-72(106)63(91-51(8)101)45-54-27-32-56-22-13-14-23-57(56)42-54;21-2(3)4/h13-14,19,21-23,27-37,42,47,49-50,60-68,100,102H,9-12,15-18,20,24-26,38-41,43-46,48H2,1-8H3,(H2,82,103)(H,90,111)(H,91,101)(H,92,107)(H,93,105)(H,94,104)(H,95,106)(H,96,108)(H,97,110)(H,98,109)(H2,84,85,88)(H2,86,87,89);21H3,(H,3,4)/t50-,60-,61+,62+,63-,64+,65-,66-,67+,68+;;/m1../s1
Cas号	123246-29-7
相关CAS号

订购信息

包装	价格	库存	纯度	备货期
大货		询价	询价	询价

Request Bulk Quote Download MSDS 电话 : +86-177 0271 9238 Email : sales@sun-shinechem.com

外观性状	固体粉末
纯度	98% Min.
存储	短期（几天到几周）为0-4摄氏度，长期（几个月）为-20摄氏度
可溶性	溶于DMSO
处理方式
运输条件	作为非危险化学品在环境温度下装运。这种产品在正常运输和海关工作期间可以稳定几周.
海关编码

Coming soon.

Targets
Mechanism
Cell study
Animal study
Clinical study

1: Sönmez Ünal G, Albak Y, Yurtcu N, Yıldız Ç, Çetin M, Durna Daştan S, Gümüş E, Çetin A. Effects of metformin and ganirelix on subcutaneous endometriosis in a mouse model of autophagy-related cell death. Turk J Obstet Gynecol. 2023 Sep 4;20(3):219-226. doi: 10.4274/tjod.galenos.2023.85616. PMID: 37667560; PMCID: PMC10478719.

2: Mannaerts B. Ganirelix and the prevention of premature luteinizing hormone surges. F S Rep. 2023 Feb 24;4(2 Suppl):56-61. doi: 10.1016/j.xfre.2023.02.009. PMID: 37223764; PMCID: PMC10201301.

3: Chatterjee S, Bandyopadhyay A. Synthesis and characterization of two potential impurities (des-ethyl-Ganirelix) generated in the Ganirelix manufacturing process. J Pept Sci. 2023 Sep;29(9):e3489. doi: 10.1002/psc.3489. Epub 2023 Apr 13. PMID: 36967632.

4: Ummiti K, Kumar JVS, Prasad MM, Subbappa PK. Evaluation of effects of temperature and humidity on the secondary structure of Ganirelix in an injectable formulation and comparison with Orgalutran® using circular dichroism spectroscopy. Chirality. 2023 Jul;35(7):427-434. doi: 10.1002/chir.23552. Epub 2023 Feb 26. PMID: 36843151.

5: Salas A, García-García P, Díaz-Rodríguez P, Évora C, Almeida TA, Delgado A. New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model. Biomed Pharmacother. 2022 Dec;156:113909. doi: 10.1016/j.biopha.2022.113909. Epub 2022 Oct 21. PMID: 36279721.

6: Li R, Gong F, Chen H, Wang Q, Qiao J. Correlation of LH level and steroid concentrations in GnRH antagonist protocol: A sub-analysis of Ganirelix phase III study of China. J Gynecol Obstet Hum Reprod. 2022 May;51(5):102363. doi: 10.1016/j.jogoh.2022.102363. Epub 2022 Mar 19. PMID: 35318120.

7: Han EJ, Lyu SW, Kwak IP, Kwon H, Choi DH, Kim JY, Park HM, Kim JW, Chang EM, Lee HJ, Kim MK, Lee HN, Kim JY, Park S, Lee WS. Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study. J Obstet Gynaecol. 2022 Aug;42(6):2197-2202. doi: 10.1080/01443615.2022.2036955. Epub 2022 Mar 7. PMID: 35254199.

8: Choudhary RA, Vora PH, Darade KK, Pandey S, Ganla KN. A Prospective Randomised Comparative Clinical Trial Study of Luteal PhaseLetrozole versus Ganirelix Acetate Administration to Prevent Severity of Early Onset OHSS in ARTs. Int J Fertil Steril. 2021 Oct;15(4):263-268. doi: 10.22074/IJFS.2021.139562.1042. Epub 2021 Oct 16. PMID: 34913294; PMCID: PMC8530210.

9: Ummiti K, Shanmukha Kumar JV. Establishment of validated stability indicating purity method based on the stress degradation behavior of gonadotropin-releasing hormone antagonist (ganirelix) in an injectable formulation using HPLC and LC- MS-QTOF. Eur J Mass Spectrom (Chichester). 2021 Apr;27(2-4):126-140. doi: 10.1177/14690667211005335. Epub 2021 Apr 7. PMID: 33823624.

10: Ummiti K, Kumar JVS. Evaluation of temperature, excipients impact on the primary structure of Ganirelix in an injectable formulation, and comparison with Orgalutran® using MALDI-TOF/TOF-MS. J Mass Spectrom. 2020 Oct;55(10):e4610. doi: 10.1002/jms.4610. PMID: 32786175.

11: Ummiti K, Kumar JVS. Determination of Amino Acid Composition of Ganirelix Acetate in an Injectable Formulation by Pre-column Derivatization with 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate. J Chromatogr Sci. 2020 Aug 21;58(8):687-694. doi: 10.1093/chromsci/bmaa030. PMID: 32676669.

12: Zhang J, Zhou X, Chen Y, Zhang Q, Li Y, Zhe J, Chen X, Chen S. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles]. Nan Fang Yi Ke Da Xue Xue Bao. 2019 Oct 30;39(10):1207-1212. Chinese. doi: 10.12122/j.issn.1673-4254.2019.10.12. PMID: 31801718; PMCID: PMC6867944.

13: Beguería R, García D, Vassena R, Rodríguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880. doi: 10.1093/humrep/dez034. PMID: 30927417.

14: Bhardwaj A, Nayan V, Sharma P, Kumar S, Pal Y, Singh J. Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix. In Silico Pharmacol. 2016 Dec;5(1):5. doi: 10.1007/s40203-017-0025-1. Epub 2017 Jul 18. PMID: 28721542; PMCID: PMC5515723.

15: Frattarelli JL, Hillensjö T, Broekmans FJ, Witjes H, Elbers J, Gordon K, Mannaerts B. Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation. Reprod Biol Endocrinol. 2013 Sep 12;11:90. doi: 10.1186/1477-7827-11-90. PMID: 24028076; PMCID: PMC3847921.

16: Qiao J, Lu G, Zhang HW, Chen H, Ma C, Olofsson JI, Witjes H, Heijnen E, Mannaerts B. A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates. Gynecol Endocrinol. 2012 Oct;28(10):800-4. doi: 10.3109/09513590.2012.665103. Epub 2012 Mar 20. PMID: 22429192.

17: Check JH, Cohen R, Amui J, Choe JK, Brasile D. Evidence that the main adverse effect of ganirelix on pregnancy and implantation rates is on the embryo rather than the endometrium. Clin Exp Obstet Gynecol. 2011;38(4):326-7. PMID: 22268265.

18: DiLuigi AJ, Engmann L, Schmidt DW, Benadiva CA, Nulsen JC. A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. Fertil Steril. 2011 Jun 30;95(8):2531-3. doi: 10.1016/j.fertnstert.2011.01.134. Epub 2011 Feb 16. PMID: 21324455.

19: Russo A, Castiglione F, Salonia A, Benigni F, Rigatti P, Montorsi F, Andersson KE, Hedlund P. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats. Eur Urol. 2011 May;59(5):868-74. doi: 10.1016/j.eururo.2010.12.007. Epub 2010 Dec 21. PMID: 21196074.

20: Check JH, Wilson C, Choe JK, Amui J, Katsoff B. A comparison of pregnancy rates following fresh and frozen embryo transfer according to the use of leuprolide acetate vs ganirelix vs cetrorelix. Clin Exp Obstet Gynecol. 2010;37(2):105-7. PMID: 21077496.

化学结构

20561 - Ganirelix acetate | CAS 123246-29-7

Ganirelix acetate

化学信息

订购信息

化学结构

快速订购

产品目录